FDA Clears Novartis Inclisiran to Lower Cholesterol With Only Two Doses a Year

Jan 4, 2022 | DAIC Articles

The U.S. Food and Drug Administration (FDA) has cleared Novartis’ inclisiran (Leqvio), the first ┬ásmall interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (LDL-C) with two doses a year, after an initial dose and one at three months.